Tadalafil for severe lung blood-pressure problems from COPD
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests whether tadalafil can improve outcomes for people with severe pulmonary hypertension caused by COPD (chronic lung disease). It compares how you do with tadalafil versus standard care, focusing on breathing symptoms and how well your heart and lungs cope.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 84 years old when you join
- Your COPD causes ongoing airflow blockage, shown by breathing test results (FEV1/FVC under 0.70 after inhaler use)
- You have severe pulmonary hypertension confirmed by heart/lung pressure tests, with specific measurements (mPAP over 20, normal wedge pressure, and high lung-vessel resistance)
- Your breathing shortness of breath is moderate to severe (WHO functional class II to IV)
- You have not taken certain pulmonary hypertension medicines recently (no PDE5 pills like sildenafil/tadalafil in the past, and no other listed PH drugs in the past 3 months)
- Your COPD treatments and, if needed, your home oxygen setup have been stable for at least 1 month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether tadalafil can improve breathlessness in people with COPD and pulmonary hypertension (high blood pressure in the lungs). It may help you breathe more easily if your symptoms are driven by this specific lung circulation problem.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.